909187-37-7

Basic information

• Product Name: 4-Methoxypyrimidin-5-ylboronicacid
• Synonyms: 4-Methoxypyrimidin-5-ylboronicacid;(4-Methoxy-5-pyriMidinyl)-boronic acid;SIHFIKAJVVQLMX-UHFFFAOYSA-N
• CAS NO: 909187-37-7
• Molecular Formula: C5H7BN2O3
• Molecular Weight: 154
• Mol File: 909187-37-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Methoxypyrimidin-5-ylboronicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxypyrimidin-5-ylboronicacid(909187-37-7)
• EPA Substance Registry System: 4-Methoxypyrimidin-5-ylboronicacid(909187-37-7)

Safety Data

• Hazardous Substances Data: 909187-37-7(Hazardous Substances Data)

Usage

Description

4-Methoxypyrimidin-5-ylboronic acid is a boronic acid derivative characterized by the presence of a methoxy group attached to a pyrimidinyl moiety. 4-Methoxypyrimidin-5-ylboronicacid exhibits unique chemical properties that make it a valuable intermediate in various organic synthesis processes.

Uses

Used in Pharmaceutical Industry:
4-Methoxypyrimidin-5-ylboronic acid is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the formation of carbon-carbon bonds through palladium-catalyzed reactions, facilitating the creation of complex molecular architectures.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Methoxypyrimidin-5-ylboronic acid serves as a versatile building block for the construction of diverse organic molecules. Its reactivity in Suzuki-Miyaura cross-coupling reactions enables the formation of carbon-carbon bonds, which is crucial for the synthesis of a wide range of organic compounds.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
4-Methoxypyrimidin-5-ylboronic acid is used as a boronic acid derivative in Suzuki-Miyaura cross-coupling reactions. This palladium-catalyzed process is essential for the formation of carbon-carbon bonds, allowing chemists to efficiently construct complex molecular structures with high selectivity and under mild conditions.

Upstream product

• 4319-85-1 5-bromo-4-methoxy-pyrimidine 

Downstream Products

• 1448866-67-8 5-(5-chloro-2-methyl-phenyl)-6-(4-chloro-2-methyl-phenyl)-1-isopropyl-2-(4-methoxy-pyrimidin-5-yl)-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one 
• 1558007-84-3 3-{(1R)-1-[5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]ethoxy}-5-(4-methoxypyrimidin-5-yl)pyridin-2-amine 
• 1445879-74-2 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(4-methoxypyrimidin 5-yl)quinoline-3-sulfonamide 

Relevant articles and documents

BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME

Provided is a compound showing excellent antifungal activity against Trichophyton fungus, which is a major causative microorganism of superficial mycosis, and high effectiveness on diseases caused by Trichophyton fungi. A biaryl derivative represented by the formula (I) or a salt thereof: wherein ring A is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered ring heteroaryl (ring A may be further condensed to form an optionally substituted fused ring); Q is CH2, C=O, NH, O, S or the like; X1, X2 and X3 are CR1 or N; Y is CH or N; Z is CR2b or N; R2a and R2b are each a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group or the like; R2a and R2b may form, together with carbon atoms bonded thereto, an optionally substituted carbocycle, or an optionally substituted heterocycle.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.